Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 study of IMM2510/SYN-2510 + chemotherapy combination in first-line NSCLC in China

Next Previous
Trial Profile

A Phase 1b/2 study of IMM2510/SYN-2510 + chemotherapy combination in first-line NSCLC in China

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMM-2510 (Primary) ; Antineoplastics
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions

Most Recent Events

  • 22 May 2025 According to Instil Bio media release, the company expects to complete enrollment of approximately 60 patients in Q3 2025. Among more than 30 NSCLC patients enrolled (including the safety run-in), more than 20 first-line NSCLC patients have been treated since the end of March.
  • 04 Mar 2025 According to Instil Bio media release, the company announced enrollment of the first patient in NSCLC in China in January 2025.
  • 14 Jan 2025 According to Instil Bio media release, the company announced that it plans to enroll first-line patients in this trial and anticipates presenting initial clinical data, including data for first-line NSCLC patients, from this trial as soon as the second half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top